Entities: BPC-157 · TB-500 · Cluster: Healing & recovery (BPC / TB-500)
BPC-157 and TB-500 are different synthetic research peptides that share a search cluster and “wolverine” marketing folklore — not the same molecule, not interchangeable, and not FDA-approved drugs. An educational comparison is about structure, naming, evidence maturity, and regulatory literacy, not a personal healing protocol.
We do not recommend BPC-157, TB-500, or any blend. We publish no dosing charts, reconstitution recipes, or stack protocols. Gray-market “research use only” vials are not medicines. Disclaimers.
Key takeaways
- Different molecules: BPC-157 is a 15–amino-acid gastric-derived sequence; TB-500 is commonly discussed as a short thymosin beta-4–related fragment — not full-length Tβ4.
- Shared folk brand: “Wolverine peptide / stack” is marketing language, usually BPC-157 ± TB-500 — not a scientific name or proven therapy.
- Evidence maturity is thin for both in high-quality human RCTs of the marketed research peptides; animal/cell data dominate.
- Both are typically framed as RUO / not approved in consumer markets — unlike labeled FDA peptide drugs.
- We refuse “which is better for healing,” blend charts, and DIY dose comparisons.
- Optional future hub: wolverine peptide explained (planned).
Questions this page answers
- One-sentence educational summary
- What is BPC-157?
- What is TB-500?
- Criteria table
- How they differ
- How they are similar
- “Wolverine” stack myth
- “Which is better for healing?” — refusal
- Why no blend / dosage chart?
- Who this comparison is for / not for
Who is this comparison for — and who is it not for?
For: readers sorting SERP/AI mashups of BPC-157 vs TB-500, students mapping the healing-peptide cluster, and anyone who needs literacy on the “wolverine” nickname without a protocol.
Not for: people seeking a buy link, a blend calculator, a “which heals tendons better” winner, or medical advice.
One-sentence educational summary
BPC-157 and TB-500 are distinct unapproved research peptides often sold and searched together under “healing” and “wolverine” folklore — they differ in sequence origin and naming, share thin human evidence as marketed products, and neither is a substitute for clinical care or an approved drug.
What is BPC-157?
BPC-157 is a pentadecapeptide (15 amino acids) whose sequence was derived from a protein studied in human gastric juice (“body protection compound”). It is not FDA-approved. Most published work is animal/cell; high-quality human RCTs are lacking. Full profile: BPC-157.
What is TB-500?
TB-500 is the common research-market name for a short synthetic peptide fragment associated with thymosin beta-4 (often described around the acetylated actin-binding motif Ac-LKKTETQ). It is not the same as full-length thymosin beta-4, and evidence for one does not automatically transfer to the other. It is not FDA-approved. Full profile: TB-500.
Criteria table
| Criterion | BPC-157 | TB-500 |
|---|---|---|
| Chemistry / naming folklore | 15–aa synthetic; gastric “BPC” sequence story | Short Tβ4-related fragment (≠ full-length Tβ4) |
| Typical length framing | Pentadecapeptide | Heptapeptide fragment narratives (verify product CoA claims) |
| Main evidence base discussed | Rodent / cell; thin human | Animal / fragment lit; human TB-500 RCTs effectively absent |
| Regulatory (U.S. consumer framing) | Not approved; covered by HHS interim 503A enforcement discretion (Oct 28, 2026) | Not approved; PCAC/compounding talk ≠ approval |
| Sport (literacy) | WADA-relevant (BPC-157 is named under S0 on the 2026 list) | Tβ4 and derivatives (e.g. TB-500) are named under S2 on the 2026 list |
| “Wolverine” association | Common primary nickname target | Common stack partner in marketing |
| DIY protocol appropriateness | Inappropriate — RUO literacy only | Inappropriate — RUO literacy only |
Table is educational, not a formulary or ranking. Regulatory and WADA lines change — check the current official sources.
How they differ
- Molecular identity: different sequences and research lineages (gastric BPC fragment story vs thymosin-β4 fragment story).
- Naming traps: TB-500 is routinely collapsed with full-length Tβ4 in AI answers — BPC-157 has a different alias set (Bepecin, PL 14736, “stable gastric pentadecapeptide”).
- Mechanism hypotheses discussed in literature differ (angiogenesis / NO-system narratives for BPC vs actin / cell-migration narratives for Tβ4-related fragments) — all hedged, mostly preclinical.
- Regulatory status is currently parallel: HHS's Oct 28, 2026 interim policy covers conditioned 503A compounding of both (with different routes), and neither is an approved U.S. drug. See the compounding status guide.
How they are similar
- Both appear in the same healing / recovery keyword cluster.
- Both are typically sold or discussed as research-use-only products, not labeled medicines.
- Both have limited high-quality human efficacy evidence as the marketed research peptides.
- Both are pulled into “wolverine stack” folklore.
- Both invite unsafe DIY dosing demand — which this site refuses.
“Wolverine” stack myth
| Folk framing | Literacy correction |
|---|---|
| “Wolverine peptide” = a formal drug | Nickname borrowed from comic-book healing — usually BPC-157 ± TB-500 marketing |
| Stack = clinically validated combo | No high-quality human trials establish a BPC+TB “protocol” |
| Same mechanism because same nickname | Nickname ≠ shared pharmacology |
| Blend vial = two studied drugs | Product quality unknown; still unapproved research materials |
A dedicated myth hub is planned: wolverine peptide explained.
“Which is better for healing?” — educational refusal
We do not declare a winner. “Better for healing” is a medical question that depends on diagnosis, evidence that mostly does not exist at the RCT level for these marketed peptides, product quality unknowns, and clinician judgment. Forum rankings and AI champion picks are not care. Curiosity closure: compare criteria (table above), then read each profile — don’t treat a blog as a treatment chooser.
Why no blend / dosage chart?
Publishing mcg charts, “BPC mornings / TB evenings,” or blend reconstitution recipes would be unsafe medical instruction for unapproved compounds. Unit-math tools elsewhere on this site are lab literacy, not prescriptions — see peptide calculator and disclaimers.
Shared safety literacy (not reassurance)
Unknown product purity, sterility, and identity are first-order risks for gray-market RUO vials — before any peptide-specific hypothesis. Sport athletes face anti-doping consequences. For compound-specific literature themes, see the profiles — this page does not invent a side-effect ranking.
Related reading
- Profiles: BPC-157 · TB-500
- Planned: wolverine peptide explained
- Fundamentals: what are peptides? · research peptides · are peptides safe?
- Lab literacy: reconstitute peptides · store peptides
- Evidence: how we evaluate evidence
Frequently asked questions
Is BPC-157 the same as TB-500?
No. They are different synthetic peptides. Sharing “wolverine” marketing and a healing search cluster does not make them interchangeable.
Which is better for healing?
We don’t pick a winner. Neither is an FDA-approved healing drug , and thin human evidence does not support a tutorial ranking.
What is the wolverine stack?
Online slang, usually for BPC-157 combined with TB-500. It is folklore branding, not a validated medical protocol.
Does TB-500 equal thymosin beta-4?
No. Full-length thymosin beta-4 and the short fragment sold as TB-500 should be kept separate for evidence literacy.
Can you publish a BPC + TB blend dose chart?
No. We don’t publish dosing or stack protocols for unapproved research peptides.
What about side effects?
Treat product-quality unknowns seriously; read each profile’s safety-literacy section and talk to a clinician about health decisions. We don’t rank “which has fewer side effects” as advice.
Sources
- Peptide Tutorials. BPC-157 profile; TB-500 profile (including the verified citations on those pages).
- U.S. Food and Drug Administration. Human drug compounding and bulk drug substances used in compounding under section 503A. Accessed November 10, 2026.
- World Anti-Doping Agency. The World Anti-Doping Code International Standard Prohibited List 2026. Accessed November 10, 2026. Confirm the current list and GlobalDRO before relying on sport status. BPC-157 is named under S0 (non-approved substances). Thymosin-β4 and its derivatives, including TB-500, are named under S2.
- Peptide Tutorials. Disclaimers; How we evaluate evidence.
Educational comparison only. Not medical advice, not a healing protocol, not a dosing or blend guide, and not a product endorsement. We don’t sell peptides. Full disclaimers.